Menu
Search
|

Menu

Close
X

Sonoma Pharmaceuticals Inc SNOA.OQ (NASDAQ Stock Exchange Capital Market)

4.35 USD
+0.07 (+1.64%)
As of Feb 22
chart
Previous Close 4.28
Open 4.33
Volume 1,215
3m Avg Volume 6,046
Today’s High 4.35
Today’s Low 4.33
52 Week High 8.18
52 Week Low 4.17
Shares Outstanding (mil) 4.40
Market Capitalization (mil) 18.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
13
FY17
14
FY16
13
FY15
14
EPS (USD)
FY18
-2.208
FY17
-1.729
FY16
-3.620
FY15
-4.473
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
1.11
8.23
Price to Book (MRQ)
vs sector
1.40
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
2.61
15.44
LT Debt to Equity (MRQ)
vs sector
1.50
12.05
Return on Investment (TTM)
vs sector
-64.54
13.63
Return on Equity (TTM)
vs sector
-67.32
15.25

EXECUTIVE LEADERSHIP

James Schutz
President, Chief Executive Officer, Director, Since 2013
Salary: $250,000.00
Bonus: --
Robert Northey
Executive Vice President - Research and Development, Since 2014
Salary: $194,000.00
Bonus: $20,000.00
Bruce Thornton
Executive Vice President - International Operations and Sales, Since 2008
Salary: $250,000.00
Bonus: --
Marc Umscheid
Chief Strategy and Marketing Officer, Since 2017
Salary: --
Bonus: --
Robert Miller
Chief Financial Officer, Chief Operating Officer, Secretary, Since 2013
Salary: $250,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1129 N Mcdowell Blvd
PETALUMA   CA   94954-1110

Phone: +1707.2830550

Sonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.

SPONSORED STORIES